IgA NEPHROPATHY

Ongoing Trials
Mycophenolate in IgA Nephropathy: Investigators at the Center for Glomerular Diseases are involved in a controlled, randomized, double blind trial of mycophenolate
(Cell Cept) versus placebo in patients with IgAN and we are actively recruiting patients. 

Completed Studies and Trials
Pilot Study of Mycophenolate in IgA Nepropathy:A study evaluating the use of mycophenolate mofetil in IgAN did not show any benefit of the use of immunosuppresion in patients with significantly reduced renal function.
(Frisch G, Lin J, Rosenstock J, Markowitz G, D'Agati V, Radhakrishnan J, Preddie D, Crew J, Valeri A, Appel G.Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial.Nephrol Dial Transplant. 2005)

Genetics of IgA Nephropathy: Extensive genetic studies are being conducted on patients at the Glomerular Disease Center with IgAN to help to identify which genes may be linked to   this disease. (Gharavi AG et al. IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23. Nat. Genetics 26:354-357 2000)

Two recent retrospective studies looked at the issues of IgA nephropathy in African American patients and systemic diseases related to IgA nephropathy (Henoch Schonlein Purpura) 
 

Other recent publications on IgA nephropathy:

Waldman M, Appel G. IgA nephropathy and Henoch Schonlein Purpura. In Current Diagnosis & Treatment in Nephrology and Hypertension ( in press)


 BACK